Witty words on data
Andrew Witty is the CEO of GlaxoSmithKline. He’s been credited with taking on a pharma company with a history of behaving badly in the past – as shown by a record $3bn fine levied by the US government last year. How much is he able or willing to change the culture of an industry, which is under pressure to alter its practices? Rebecca Coombes finds out.
Also this week, Michael Dowling, president and CEO of the North Shore-LIJ Health System in New York, has built his organisation up from two hospitals undergoing a difficult merger into a giant integrated system. He explains his no-nonsense approach to making change work.
See also:
BMJ Open data campaign
Andrew Witty: the acceptable face of big pharma?
Audio chapters:
Andrew Witty on data: 1:13
Michael Dowling on change: 12:7








Re: Better management of patients with multimorbidity
Published 17 May 2013
Re: India must raise the status of primary care
Published 17 May 2013
Re: Partnering with patients
Published 17 May 2013
Re: Rescue boards are set up in England to deal with “significant deterioration” in A&E departments
Published 17 May 2013